Srikripa Devarakonda
Stock Analyst at Truist Securities
(1.96)
# 3,179
Out of 4,944 analysts
65
Total ratings
35%
Success rate
-4.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $812 | $570.20 | +42.41% | 8 | Aug 11, 2025 | |
| INCY Incyte | Maintains: Hold | $73 → $79 | $86.13 | -8.28% | 11 | Jul 30, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $6.89 | +59.65% | 1 | May 5, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $134.19 | +48.30% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $14.05 | +77.94% | 5 | Apr 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $55.67 | +36.52% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $673.15 | +54.20% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $203.72 | +6.52% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $25.05 | +27.74% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $13.69 | +265.23% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $32.00 | +40.63% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $40.44 | +31.06% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.66 | +3,162.84% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $7.48 | +100.53% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $10.41 | +245.82% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $37.44 | +86.97% | 4 | May 29, 2024 |
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $570.20
Upside: +42.41%
Incyte
Jul 30, 2025
Maintains: Hold
Price Target: $73 → $79
Current: $86.13
Upside: -8.28%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $6.89
Upside: +59.65%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $134.19
Upside: +48.30%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $14.05
Upside: +77.94%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $55.67
Upside: +36.52%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $673.15
Upside: +54.20%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $203.72
Upside: +6.52%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $25.05
Upside: +27.74%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $13.69
Upside: +265.23%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $32.00
Upside: +40.63%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $40.44
Upside: +31.06%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.66
Upside: +3,162.84%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $7.48
Upside: +100.53%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $10.41
Upside: +245.82%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $37.44
Upside: +86.97%